Dante Labs

Trending Articles

  1. LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
  2. Fasenra for EGPA: addressing unmet needs Benralizumab could offer patients with EGPA more treatment options, while reducing dependency on oral corticosteroids
  3. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
  4. Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
  5. Bristol Myers Squibb and Cellares partner to expand CAR-T manufacturing capabilities Cellares will optimise and automate select Bristol Myers Squibb CAR-T cell therapies onto its high-throughput manufacturing program, the Cell Shuttle

Upcoming event

Cleanroom Conference UK

22–23 May 2024 | Exhibition | Birmingham, UK See all

Related Content

Research & Development

Dante Labs highlights advancements to its drug discovery programme

Company announces rebranding to Dante Genomics to reflect its broader global efforts
Finance

Dante Labs appoints Mark Van Oene to board of directors

Van Oene said: “I’m excited to be joining Dante’s board in order to help scale the business as the need for genomics in healthcare is realised
Manufacturing

Dante Labs invests in COVID-19 sequencing surveillance program

The company has analysed two million and a half COVID-19 RT-PCR tests and sequenced more than 30,000 human whole genomes
Subscribe now